Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma

Keisuke Shigeta1 | Masanori Hasegawa2 | Eiji Kikuchi1,3 | Yota Yasumizu1 | Takeo Kosaka1 | Ryuichi Mizuno1 | Shuji Mikami4 | Akira Miyajima2 | Donald Kufe5 | Mototsugu Oya1

Abbreviations: ABC, ATP-binding cassette; ABCB1, ATP-binding cassette transporter B1; CDDP, cisplatin; CHX, cycloheximide; CSS, cancer-specific survival; GSH, glutathione; MDR1, multiple drug resistance 1; MIBC, muscle-invasive bladder cancer; MUC1-C, mucin 1 C-terminal subunit; RC, radical cystectomy; RNU, radical nephroureterectomy; ROS, reactive oxygen species; SE, standard error; SD, standard deviation; NAC, neoadjuvant chemotherapy; UC, urothelial carcinoma; UTUC, upper tract urothelial carcinoma; xCT, X-cystine/glutamate transporter.

Abstract
Mucin 1 C-terminal subunit (MUC1-C) has been introduced as a key regulator for acquiring drug resistance in various cancers, but the functional role of MUC1-C in urothelial carcinoma (UC) cells remains unknown. We aimed to elucidate the molecular mechanisms underlying the acquisition of cisplatin (CDDP) resistance through MUC1-C oncoprotein in UC cells. MUC1-C expression was examined immunohistochemically in tumor specimens of 159 UC patients who received CDDP-based perioperative chemotherapy. As a result, moderate to high MUC1-C expression was independently associated with poor survival in UC patients. Using human bladder cancer cell lines and CDDP-resistant (CR) cell lines, we compared the expression levels of MUC1-C, multiple drug resistance 1 (MDR1), the PI3K-AKT-mTOR pathway, and x-cystine/glutamate transporter (xCT) to elucidate the biological mechanisms contributing to the acquisition of chemoresistance. MUC1-C was strongly expressed in CR cell lines, followed with MDR1 expression via activation of the PI3K-AKT-mTOR pathway, and x-cystine/glutamate transporter (xCT) to elucidate the biological mechanisms contributing to the acquisition of chemoresistance. MUC1-C was strongly expressed in CR cell lines, followed with MDR1 expression via activation of the PI3K-AKT-mTOR pathway. MUC1-C also stabilized the expression of xCT, which enhanced antioxidant defenses by increasing intracellular glutathione (GSH) levels. MUC1 down-regulation showed MDR1 inhibition along with PI3K-AKT-mTOR pathway suppression. Moreover, it inhibited xCT stabilization and resulted in significant decreases in intracellular GSH levels and increased reactive oxygen species (ROS) generation. The MUC1-C inhibitor restored sensitivity to CDDP in CR cells and UC murine xenograft models. In conclusion, we found that MUC1-C plays a pivotal role in the acquisition of CDDP resistance in UC cells, and therefore the combined treatment of CDDP with a MUC1-C inhibitor may become a novel therapeutic option in CR UC patients.

KEYWORDS
GO-203, MDR1, MUC1-C, PI3K-AKT-mTOR, urothelial carcinoma, xCT
1 INTRODUCTION

UC comprises cancers of the renal pelvis, ureter, and bladder epithelium, and is one of the most aggressive malignancies that remains extremely challenging to treat.\(^1\) CDDP-based combination chemotherapy has been the gold standard first-line treatment for metastatic UC.\(^2,3\) Although immune checkpoint inhibitors have certain clinical benefits for platinum-resistant metastatic UC, response rates only reach 15%-20%,\(^4\) and, therefore, basic treatment still relies on CDDP-based chemotherapy because of its strong cytotoxic effects on UC cells. However, one of the main concerns associated with CDDP-based chemotherapy is that the efficacy of the treatment may decrease due to the development of chemoresistance. Therefore, a new therapeutic strategy for enhancing the efficacy of CDDP is strongly needed against UC.

While the mechanisms underlying chemotherapeutic resistance remain unknown in UC cells, one of the well known factors responsible for drug resistance is the overexpression of ABC transporters that function as an energy-dependent efflux pump to discharge cytotoxic drugs from tumor cells.\(^5\) Human ABCB1, also known as the gene responsible for MDR1, is one of the well recognized ABC transporters with the broadest substrate specificity.\(^6\) In UC cells, previous studies have indicated that MDR1 expression was strongly associated with poor clinical outcomes and chemoresistance.\(^7\) Although the structure and function of ABCB1/MDR1 have been examined extensively, pharmacological inhibitors of this transporter have not yet been translated into a clinical target because of toxicities, which are primarily attributed to its critical functions in various normal tissues.\(^8,9\)

Another key agent for developing CDDP resistance in UC cells may be through the overexpression of xCT, a member of the family of heterodimeric amino acid transporters, which are known as cystine/glutamate transporters.\(^10,11\) We reported previously that CD44 variant isoforms stabilized xCT in a UC cell line, which enhanced intracellular GSH synthesis through the uptake of cysteine, and contributed to the suppression of ROS production.\(^12,13\) Thus, the stabilization of xCT may reinforce defenses against oxidative stress, resulting in CDDP resistance. Although xCT has the potential as a target for overcoming chemoresistance, limited information is currently available on the regulation of xCT expression in human UC cells.

Due to the complexity and numerous mechanisms of CDDP resistance in UC patients, we suspect that mucin 1 (MUC1) is a key regulator for overcoming chemoresistance in UC cells. MUC1 is a transmembrane heterodimeric glycoprotein that is normally expressed around normal tissue of the lung, breast, and prostate. However, previous studies have found that MUC1 was aberrantly glycosylated and overexpressed in many carcinomas and associated with poor clinical outcomes.\(^14\) MUC1 is processed by autocleavage into 2 subunits, the extracellular N-terminal subunit and transmembrane C-terminal subunit. These 2 subunits usually form a stable heterodimeric complex at the cell membrane. However, in cancer cells, the MUC1-C cytoplasmic domain may separate from MUC1-C and function as an oncoprotein inside the cell cytoplasm.\(^15\) MUC1-C is known to activate signaling pathways including the PI3K/AKT pathway and ERK pathway, and interacts with β-catenin to be transported to the nucleus.\(^16\) In the nucleus, the relationship between MUC1-C and certain transcription factors promotes the expression of genes involved in cancer proliferation, survival, and chemoresistance.\(^17,18\)

Recent evidence has demonstrated a pivotal role for MUC1-C in therapeutic resistance in certain cancer cell types. Previous studies have revealed that overexpression of MUC1-C induced the up-regulation of multiple drug protein-1 in pancreatic cancer and MDR1 in bladder cancer.\(^7,19\) Moreover, MUC1-C was recently shown to form a complex with xCT that regulated intracellular GSH levels in breast cancer.\(^12\) These findings suggest that MUC1-C functions as a key co-factor, contributing to chemoresistance in cancer cells. However, only a few insights are currently available on the functional role of MUC1-C in UC cells.

The aims of the present study were to investigate: (1) the prognostic role of MUC1-C in tumor recurrence and cancer death in UC patients treated with CDDP chemotherapy; and (2) the molecular mechanisms underlying the acquisition of CDDP resistance through the MUC1-C oncoprotein in UC cells.

2 MATERIALS AND METHODS

2.1 Tissue samples

Among 226 patients who were treated with RNU for UTUC at Keio university hospital between 1990 and 2017, 89 received CDDP-based adjuvant chemotherapy. Furthermore, among the 121 MIBC patients who underwent RC between 2004 to 2017, we identified 70 MIBC patients who received CDDP-based neoadjuvant chemotherapy. Tissue samples were obtained from consenting patients in the present study, which was approved by the Keio University Ethics Committee. All specimens were fixed in 10% formalin and embedded in paraffin, and all slides were re-reviewed by genitourinary pathologists. Tumors were staged according to the American Joint Committee on Cancer-Union Internationale Contre le Cancer TNM classification. Tumor grading was assessed according to the 2004 WHO/International Society of Urology Pathology consensus classification.\(^20\) Lymphovascular invasion (LVI) was defined as the presence of tumor cells within an endothelium-lined space without underlying muscular walls.\(^21\)

2.2 Immunohistochemistry

Sections (4 µm thickness) of formalin-fixed and paraffin-embedded material were evaluated. Sections were deparaffinized in xylene and rehydrated in graded alcohol and distilled water. After antigen retrieval with citric acid (pH 6.0) at 120°C for 10 min, endogenous peroxidase activity was blocked with 1% hydrogen peroxide for 15 min followed by washing with distilled water. To bind non-specific
antigens, sections were incubated at room temperature for 15 min with 5% skimmed milk in PBS. Sections were then incubated at 4°C overnight with an anti-MUC1-C Armenian hamster mAb (1:100 dilution; Thermo Scientific, Fremont, CA, USA). After washing with PBS, tissue sections were incubated with a rabbit anti-Armenian hamster secondary Ab (1:200 dilution; Abcam, Tokyo, Japan) for 60 min. Color was developed with 3,3′-diaminobenzidine tetrahydrochloride in 50 mmol/L Tris-HCl (pH 7.5) containing 0.005% hydrogen peroxide. Sections were then counterstained with hematoxylin.

To assess MUC1-C staining, cancer cells with positive staining in the cell cytoplasm were counted in at least 10 representative fields, and the mean percentage of positive cancer cells and staining intensity stratified from 0 to 3 (0: no staining; 1: low staining; 2: moderate staining; 3: strong staining) were estimated. The histoscore (H-score) was calculated by applying the following formula: mean percentage × intensity (range 0-300), which means the mean H-score was 60 (range: 0-240), and we applied receiver operating curve (ROC) analysis to define the cut-off value. As a result, ROC analysis revealed that the cut-off value: H-score < 30 was the best cut-off line for defining the low MUC1-C expression group, as the area under curve (AUC) was 0.727 for patients with UTUC (P = .001). Furthermore, a cut-off value ≥ 90 was the best cut-off value for defining the high MUC1-C expression group, as the AUC was 0.689 for patients with UTUC (P = .040). Thus, we defined an H-score of 30-90 as moderate MUC1-C expression.

### 2.3 Cell culture

Two human bladder cancer cell lines, T24 and UMUC3 (WT), were obtained from the American Type Culture Collection (Rockville, MD, USA). The 2 cell lines were grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum and 100 units/ml of penicillin/streptomycin. We generated CR cells, T24CR and UMUC3CR, by increasing the CDDP concentration up to 30 μmol/L within 12 mo.

Cells were treated with CDDP (Nippon Kayaku) and NVP-BEZ235, a dual PI3K and mTORC1/2 inhibitor (Novartis). CHX (Sigma Aldrich) was applied to WT and CR cells to compare xCT staining. In addition, GO-203 (Genus Oncology), a MUC1-C inhibitor, and the control peptide CP-2 (Genus Oncology) were used alone or with CDDP to evaluate cytotoxic effects.

### 2.4 RT-PCR analysis

In the quantitative RT-PCR analysis, cDNA synthesis was performed with 1 μg total RNA using the High Capacity Reverse Transcription Kit (Applied Biosystems). cDNA samples were amplified using TaqMan® Fast Universal PCR Master Mix (2x) (Applied Biosystems). The primers used for reverse transcription and amplification were as follows: MUC1-C (Hs00159357_m1), ABCB1 (Hs00184500_m1), and β-actin (Hs01060665_g1).

### 2.5 Western blotting

Whole cell extracts were obtained using RIPA buffer composed of 50 mmol/L Tris-HCl (pH 7.5), 15 mmol/L NaCl, 1% NP-40, 0.5% deoxycholate, and 0.1% sodium dodecyl sulfate and containing protease inhibitors. For the western blotting analysis, 30 μg of total protein was loaded onto a 12.5% sodium dodecyl sulfate-polyacrylamide gel, electrophoresed, and then transferred to a nitrocellulose membrane. The membrane was blocked at 4°C overnight in TBS containing 5% Phospho Blocker Blocking Reagent and 0.2% Tween-20, and then incubated at 4°C overnight with the primary Abs for MUC1-C (1:500 dilution), t-AKT (1:1000 dilution, Cell Signaling, Beverly, MA, USA), p-AKT (1:1000 dilution, Cell Signaling), t-mTOR (1:1000 dilution, Cell Signaling), p-mTOR (1:1000 dilution, Cell Signaling), t-S6K1 (1:1000 dilution, Cell Signaling), p-S6K1 (1:1000 dilution, Cell Signaling), xCT (1:500 dilution, Abcam), and MDR1 (1:250, dilution, Thermo Scientific). The blots were incubated with a peroxidase-labeled secondary Ab for 1 h. After PBS washing, signals were detected using enhanced chemiluminescence reagents with the ECL plus Western Blotting Detection System and analyzed using the LAS 3000 system (GE Healthcare).

### 2.6 Immunofluorescence staining

To measure immunofluorescence, 2.0 × 10⁴ cells were seeded onto 6-well plates. After 24 h, cells were rinsed once with room temperature PBS, fixed with 4% formaldehyde for 20 min, and washed 3 times with PBS. Cells were permeabilized with 0.2% Triton TMX-100 for 30 min during 1% BSA blocking. Cells were exposed to the primary Abs for MDR1 (dilution 1:250) or MUC1-C (dilution 1:500) for 30 min and thereafter with an anti-mouse Alexa Fluor 555 Ab (dilution 1:200, Invitrogen, USA) and Armenian hamster Alexa Fluor 488 Ab (dilution 1:200, Invitrogen). Coverslips were mounted onto glass slides with 4′,6-diamidino-2-phenylindole (DAPI). A confocal microscope (Olympus, Tokyo, Japan) was used to observe all stained slices.

### 2.7 Cell viability assay

T24WT, T24CR, UMUC3WT, and UMUC3CR cells were seeded onto 96-well plates, allowed to attach for 24 h, and then treated with various concentrations of CDDP, and with GO-203. After a 48-h exposure to the drugs, WST-8 reagents were added to each well and cells were incubated for 1 h. Cell viability was estimated using a plate reader by reading the color intensities at 450 and 620 nm.

### 2.8 Intracellular GSH and ROS measurements

Regarding cellular GSH measurements, 1 × 10⁴ cells in 100 μL of culture medium were plated on a 96-multiwell white plate and
allowed to attach for 24 h. Following the addition of 100 μL of GSH-Glo Reagent (Promega Corp, Tokyo, Japan) at room temperature for 30 min, 100 μL of the luciferin detection reagent was added at room temperature for an additional 15 min. The luminescence intensity of each well was recorded on a GloMax™ 96 Microplate Luminometer. Intracellular ROS levels were assessed using dichlorodihydrofluorescein (DCF) fluorescence staining (C6827; Invitrogen). Regarding cellular ROS measurements, T24WT, T24CR, UMUC3WT, and UMUC3CR cells were treated with control vehicle and CDDP at 10 μmol/L for 24 h, and then harvested and diluted in PBS to 1 × 10^5 cells/well in 6-well plates for 24 h. These cells were incubated with 10 μmol/L dichlorodihydrofluorescein diacetate (H₂DCFDA) at 37°C for 15 min and washed twice with PBS. The mean intensity of DCF fluorescence was assessed using Image StreamX/Flow Sign flow cytometry.

2.9 | Small interfering RNA and transfection

MUC1-C and MDR1 expression was transiently down-regulated using the following predesigned siRNA directed against siMUC1 (siMUC1#1 and siMUC1#2) and siMDR1, respectively. A mock-transfected control was prepared using the transfection reagent with non-targeting control (NTC) siRNA. The sense sequences of siRNAs for MUC1, MDR1, and NTC were as follows:

- siMUC1#1: CCACCAAUUUCUCGGACAC, siMUC1#2: GAUCG UAGCCCUAUGAGA, siMDR1: GGGUUCUUCAUGAAUGGAA, and NTC siRNA: UAGCGACUAACACAUCAA.

Cells were transiently transfected with 5 nmol of the respective siRNAs using Dharmafect (Dharmacon, Lafayette, CO, USA). After 24 h, siRNA was removed by replacing the culture medium with fresh RPMI 1640 medium containing 10% FBS, and cells were incubated for another 24 h.

2.10 | UC murine xenograft models

4- to 6-wk-old female BALB/c-nu/nu mice with an average body weight of 20 g were obtained from Sankyo Lab Service Co. UMUC3CR cells (2 × 10^5 cells), suspended in 100 μL of Matrigel (Becton Dickinson Labware), were implanted subcutaneously into the flank of each nude mouse. When a mouse developed a palpable tumor, it was assigned randomly to 1 of 4 groups. Each group of 8 mice was treated with vehicle control of CP-2 (daily ip injection of 18 mg/kg), CDDP alone (ip injection of 5 mg/kg on days 1 and 15), GO-203 alone (daily ip injection of 18 mg/kg), or a combination of CDDP and GO-203. Tumor volume was calculated according to the formula a^2 × b × 0.52, where a and b are the smallest and largest diameters, respectively. At 25 d after drug administration, the mice were sacrificed and the subcutaneous tumors were harvested. All procedures involving animals and their care in this study were approved by the Animal Care Committee of Keio University School of Medicine.

2.11 | Statistical analysis

The relationship between MUC1-C expression and clinicopathological features was assessed using the chi-squared (χ²) test. CSS was defined as the time from RNU to UTUC-related death, and time from RC to bladder cancer-related death. CSS rates were estimated using the Kaplan-Meier method and compared with the Log-rank test. Univariate and multivariate Cox proportional hazards regression analyses were performed to assess prognostic indicators for disease recurrence and survival. In the in vitro study, each value represents the mean ± SE of at least 3 individual experiments. In the in vivo study, each value represents the mean ± standard deviation (SD) of at least 3 individual experiments. The difference between 2 groups in the in vitro and in vivo study was assessed using two-tailed Student t test. The level of significance was set at P < .05. These analyses were undertaken using Statistical Package of Social Sciences software, version 24.0 (SPSS).

3 | RESULTS

3.1 | Clinical role of MUC1-C expression in UC human samples treated with perioperative CDDP-based chemotherapy

The backgrounds of both the patients with UTUC and the patients with MIBC are shown in Table 1. The 89 patients with UTUC were classified into either a moderate to high MUC1-C expression group (n = 43, 48.3%) or a low MUC1-C expression group (n = 46, 51.7%) based on the cut-off levels. Representative MUC1-C staining in UTUC samples is shown in Figure 1A. Here, 33 (37.1%) patients developed tumor recurrence and 32 (36.0%) died due to cancer-related causes. No significant differences were observed in the patient characteristics of both groups (Table 1). Based on multivariate Cox regression analysis, moderate to high MUC1-C expression was one of the independent prognostic factors for both disease recurrence and cancer-specific death (hazard ratio (HR) = 2.22, P = .042 and HR = 3.04, P = .006, respectively) (Table 2).

We further confirmed the association of oncological outcomes and MUC1-C expression in 70 MIBC patients who received CDDP-based neoadjuvant chemotherapy (NAC) before RC. By using the same cut-off level for the H-score as in UTUC, 32 (45.7%) patients showed moderate to high MUC1-C expression, while 38 (54.3%) showed low MUC1-C expression. Representative MUC1-C staining of MIBC is shown in Figure 1B. Overall, 31 (44.3%) patients developed tumor recurrence and 30 (42.9%) patients died due to cancer-related causes. Multivariate analysis revealed that moderate to high MUC1-C expression remained as an independent risk factor for both disease recurrence and cancer-specific death (HR = 2.62, P = .007 and HR = 4.09, P = .001, respectively) (Table S1). Figure 1C, D shows the clinical
### Table 1: Patient characteristics of upper tract urothelial carcinoma and muscle invasive bladder cancer patients

| Patient characteristics | UTUC | Low MUC1-C expression | Moderate to high MUC1-C expression | P-value | MIBC | Low MUC1-C expression | Moderate to high MUC1-C expression | P-value |
|-------------------------|------|-----------------------|-----------------------------------|---------|------|-----------------------|-----------------------------------|---------|
| Age                     |      |                       |                                   |         |      |                       |                                   |         |
| <75                     | 50 (56.2) | 25 (54.3) | 25 (58.1) | .442 | 45 (64.3) | 27 (71.1) | 18 (56.2) | .150 |
| ≥75                     | 39 (43.8) | 21 (45.7) | 18 (41.9) | 25 (35.7) | 11 (28.9) | 14 (43.8) |         |       |
| Sex                     |      |                       |                                   |         |      |                       |                                   |         |
| male                    | 65 (73.0) | 35 (76.1) | 30 (69.8) | .333 | 56 (80.0) | 28 (73.7) | 28 (87.5) | .127 |
| female                  | 24 (27.0) | 11 (23.9) | 13 (30.2) | 14 (20.0) | 10 (26.3) | 4 (12.5) |         |       |
| Tumor location          |      |                       |                                   |         |      |                       |                                   |         |
| pelvis                  | 44 (49.4) | 25 (54.3) | 19 (44.2) | .228 | -     | -                    | -                   | -       |
| ureter                  | 45 (5.6) | 21 (45.7) | 24 (55.8) |         | -     | -                    | -                   |       |
| Pathological T stage    |      |                       |                                   |         |      |                       |                                   |         |
| <3                      | 18 (20.2) | 13 (28.3) | 5 (11.6) | .054 | 41 (58.6) | 26 (68.4) | 15 (46.9) | .057 |
| ≥3                      | 71 (79.8) | 33 (71.7) | 38 (88.4) | 29 (41.4) | 12 (31.6) | 17 (53.1) |         |       |
| Tumor grade             |      |                       |                                   |         |      |                       |                                   |         |
| low                     | 15 (16.9) | 10 (21.7) | 5 (11.6) | .161 | 17 (24.3) | 8 (21.1) | 9 (28.1) | .341 |
| high                    | 74 (83.1) | 36 (78.3) | 38 (88.4) | 53 (75.7) | 30 (78.9) | 23 (71.9) |         |       |
| LVI                     |      |                       |                                   |         |      |                       |                                   |         |
| absent                  | 33 (37.1) | 21 (45.7) | 12 (27.9) | .065 | 39 (55.7) | 26 (68.4) | 13 (40.6) | .018 |
| present                 | 56 (62.9) | 25 (54.3) | 31 (72.1) | 31 (44.3) | 12 (31.6) | 19 (59.4) |         |       |
| Concomitant CIS         |      |                       |                                   |         |      |                       |                                   |         |
| no                      | 63 (70.8) | 32 (69.6) | 31 (72.1) | .489 | 51 (72.9) | 31 (81.6) | 20 (62.5) | .064 |
| yes                     | 26 (29.2) | 14 (30.4) | 12 (27.9) | 19 (27.1) | 7 (18.4) | 12 (37.5) |         |       |
| Disease recurrence      |      |                       |                                   |         |      |                       |                                   |         |
| no                      | 56 (62.9) | 36 (78.3) | 20 (46.5) | .002 | 39 (55.7) | 29 (76.3) | 10 (31.2) | <.001 |
| yes                     | 33 (37.1) | 10 (21.7) | 23 (53.5) | 31 (44.3) | 9 (23.7) | 22 (68.8) |         |       |
| Cancer-specific death   |      |                       |                                   |         |      |                       |                                   |         |
| no                      | 57 (64.0) | 37 (80.4) | 20 (46.5) | .001 | 40 (57.1) | 30 (78.9) | 10 (31.2) | <.001 |
| yes                     | 32 (36.0) | 9 (19.6)  | 23 (53.5) | 30 (42.9) | 8 (21.1) | 22 (68.8) |         |       |

Abbreviations: CIS, carcinoma in situ; LVI, lymphovascular invasion; MIBC, muscle invasive bladder cancer; UTUC, upper tract urothelial carcinoma.
outcomes of patients with UTUC and patients with MIBC treated with CDDP-based chemotherapy classified by MUC1-C expression. The Kaplan-Meier curve revealed that 5-y CSS rate in patients with UTUC was 53.5% in the moderate to high MUC1-C expression group, which was significantly lower than that in the low MUC1-C expression group (76.1%, \( P = .011 \); Figure 1C). In patients with MIBC treated with NAC, the 5-y CSS rate was 33.3% in the moderate to high MUC1-C expression group, which was significantly lower than that in the low MUC1-C expression group (77.3%, \( P < .001 \); Figure 1D).

3.2 | Molecular mechanisms underlying the acquisition of CDDP resistance through the MUC1-C oncoprotein in UC cells

3.2.1 | MUC1-C mRNA and protein expression levels are high in CR UC cells

To confirm the chemoresistance of the T24CR cells and UMUC3CR cell lines (Figure 2A upper panel), we compared the cell viabilities of WT and CR cells with various concentrations of CDDP for 48 h. The
TABLE 2  Uni- and multivariate Cox's regression analyses for oncological outcomes of upper tract urothelial carcinoma patients treated with radical nephroureterectomy and adjuvant chemotherapy

| Clinical indicators                        | Disease recurrence | Cancer-specific death |
|-------------------------------------------|-------------------|-----------------------|
|                                          | Univariate        | Multivariate          | Univariate        | Multivariate          |
|                                          | HR 95% CI p-value | HR 95% CI p-value     | HR 95% CI p-value | HR 95% CI p-value     |
| Age (≥75 vs <75)                          | 1.66 0.83-3.31 .150| 2.33 1.15-4.74 .019   | 2.41 1.18-4.94 .016|
| Sex (male vs female)                      | 1.78 0.86-3.68 .119| 2.12 1.02-4.40 .044   | 1.84 0.84-4.03 .128|
| Tumor location (ureter vs renal pelvis)   | 1.86 0.91-3.80 .090| 1.63 0.80-3.33 .183   |                   |
| Pathological T stage (≥3 vs <3)           | 5.00 1.75-14.3 .003| 3.80 1.32-10.9 .014   | 3.89 1.49-10.1 .005|
| Tumor grade (high vs low)                 | 4.22 1.01-17.5 .049| 2.79 1.34-5.84 .006   | 3.04 1.00-4.47 .050|
| LVI (positive vs negative)                | 3.38 1.39-8.20 .007| 1.77 0.81-3.85 .149   | 1.36 0.52-3.52 .527|
| Concomitant CIS (yes vs no)               | 1.55 0.62-3.86 .347| 0.82-8.85 .104        |                   |
| MUC1-C expression (moderate to high vs low)| 2.51 1.19-5.32 .016| 2.22 1.03-4.78 .042   | 2.55 1.17-5.56 .018|
| p-value                                    | 0.75 0.50-1.15 .019| 3.89 1.49-10.1 .005   | 3.82 1.46-10.0 .004|

Abbreviations: CI, confidence interval; CIS, carcinoma in situ; HR, hazard ratio; LVI, lymphovascular invasion.

IC50 value was 3.8-fold higher in T24CR cells than in T24WT cells (17.1 μmol/L vs 4.5 μmol/L; Figure 2A middle panel). Similarly, the IC50 value was 3.8-fold higher in UMUC3CR cells than in UMUC3WT cells (58.3 μmol/L vs 15.3 μmol/L; Figure 2A, lower panel). We analyzed the relative mRNA and protein expression levels of MUC1-C in WT and CR cell lines (Figure 2B, C, respectively). According to the RT-PCR analysis, MUC1-C mRNA levels were higher in T24CR cells than in T24WT cells (the mRNA level in T24CR cells was 1.75 ± 0.15 relative to that of T24WT cells, P = .040, Figure 2B, upper panel) and in UMUC3CR cells than in UMUC3WT cells (the mRNA level in UMUC3CR cells was 1.83 ± 0.11 relative to that of UMUC3WT, P = .018; Figure 2B, lower panel). Furthermore, the western blot analysis indicated that MUC1-C protein levels were higher in both T24CR (Figure 2C, upper panel) and UMUC3CR (Figure 2C, lower panel) cells than in WT cells.

3.2.2  MUC1-C elevates ABCB1/MDR1 expression by activating the PI3K-AKT-mTOR pathway

We confirmed that the mRNA level of ABCB1 was higher in T24CR (Figure 2D, upper panel) and UMUC3CR (Figure 2D, lower panel) cells than in WT cells. ABCB1 mRNA levels in T24CR cells were 2.27 ± 0.17 relative to that in T24WT cells (P = .009). ABCB1 mRNA levels in UMUC3CR cells were 2.62 ± 0.23 relative to that in UMUC3WT cells (P = .004).

Furthermore, the protein level of MDR1 was higher in both CR cells (Figure 2E; T24, upper panel; UTUC3, lower panel). In addition to the increase in ABCB1/MDR1 expression in T24CR and UMUC3CR cell lines, we confirmed that the phosphorylation of AKT (p-AKT), p-mTOR, and p-S6K1 was higher in CR cells than in WT cells. These results indicated that ABCB1/MDR1 expression was regulated by MUC1-C via the activation of the PI3K-AKT-mTOR signaling pathway and may enhance CDDP discharge outside tumor cells. Immunofluorescence images also showed that MUC1-C and MDR1 staining was stronger in CR cell lines than in WT cells (Figure 2F).

3.2.3  Down-regulation of MUC1 recovers CDDP sensitivity

To confirm whether MUC1-C is associated with CDDP resistance in UC cells, we silenced the expression of MUC1 in T24CR and UMUC3CR cells. By transfecting siRNA for MUC1, the relative mRNA level of MUC1-C was significantly down-regulated (Figure 3A; T24CR, upper panel; UMUC3CR, lower panel). Western blot analysis indicated that the protein expression of MUC1-C was weaker in both CR cell lines transfected with both siMUC1#1 and siMUC1#2 than in those transfected with an NTC (Figure 3B; T24CR, upper panel; UMUC3CR, lower panel). Knockdown of MUC1 indicated that the protein levels of p-AKT, p-mTOR, p-S6K1, and MDR1 were all reduced. After exposure to 20 μmol/L CDDP, the cell viabilities of T24CR cell lines transfected with siMUC1#1 and siMUC1#2 were significantly lower (19.4 ± 5.0 and 35.7 ± 1.1%, respectively) than that of the CR cell line transfected with NTC (55.7 ± 3.8%; Figure 3C, upper panel). Similarly, the cell viabilities of UMUC3CR cell lines transfected with siMUC1#1 and siMUC1#2 were significantly lower (23.1 ± 1.4 and 39.8 ± 4.3%, respectively) than that of the CR cell line transfected with the NTC (78.8 ± 1.8%; Figure 3C, lower panel). To clarify whether ABCB1/MDR1 was responsible for resistance to CDDP, we silenced ABCB1 in CR cell lines and also used NVP-BEZ235 to confirm whether the PI3K-AKT-mTOR pathway was responsible for MDR1 expression (Figure S1). Silencing of ABCB1 in T24CR and UMUC3CR cells markedly increased the sensitivity to CDDP. Following the addition of NVP-BEZ235, the relative mRNA level of ABCB1 was significantly inhibited and the western
FIGURE 2  Generation of cisplatin (CDDP)-resistant cancer cells from 2 urothelial cancer cell lines and comparisons of the expression of mucin 1 C-terminal subunit (MUC1-C). A, Acquired CDDP resistance in T24 and UMUC3 urothelial cancer cells. T24CR and UMUC3CR cells were generated by exposing the corresponding wild-type (T24WT and UMUC3WT) cells to an increasing concentration of 3 μM CDDP over 12 mo. Brief schema showing the generation of CDDP-resistant (CR) cell lines (upper panel). Graphs show changes in cytotoxicity between WT and CR cells of T24 (middle panel) and UMUC3 cells (lower panel) exposed to various concentrations of CDDP for 48 h. ** P < .01. *** P < .001. B, mRNA levels of MUC1-C in WT and CR cells measured by RT-PCR (upper panel, T24WT vs T24CR; lower panel, UMUC3WT vs UMUC3CR). * P < .05. C, Protein levels of MUC1-C in WT and CR cells measured by a western blot analysis (upper panel, T24WT vs T24CR; lower panel, UMUC3WT vs UMUC3CR). D, mRNA level of ABCB1 (responsive gene of MDR1) in WT and CR cells (upper panel, T24WT vs T24CR; lower panel, UMUC3WT vs UMUC3CR). ** P < .01. E, Protein expression levels of total-AKT, p-AKT, total-mTOR, p-mTOR, total-S6K1, p-S6K1, MDR1, and β-actin in WT and CR cells (upper panel, T24WT vs T24CR; lower panel, UMUC3WT vs UMUC3CR). F, Immunofluorescence staining of MDR1 and MUC1-C in T24WT, T24CR, UMUC3WT, and UMUC3CR cells. The nucleus was stained by DAPI, MUC1-C was stained by Alexa Fluor 488, and MDR1 was stained by an Alexa Fluor 555 antibody.

FIGURE 3  Mucin 1 C-terminal subunit (MUC1) knockdown downregulates multiple drug resistance 1 (MDR1) via the inhibition of the PI3K-AKT-mTOR pathway and increases cisplatin (CDDP) sensitivity in CDDP-resistant (CR) cells. A, mRNA expression of MUC1-C was down-regulated with siRNA for MUC1 (siMUC1#1 and siMUC1#2), but not with siRNA for a non-targeting control (NTC) (upper panel, T24CR; lower panel, UMUC3CR). *** P < .001. B, Western blot analysis of MUC1-C, total-AKT, p-AKT, total-mTOR, p-mTOR, total-S6K1, p-S6K1, MDR1, and β-actin after transfection with siRNA for NTC and MUC1 (siMUC1#1 and siMUC1#2) (upper panel, T24CR; lower panel, UMUC3CR). C, The graph shows the viability of cells exposed to various concentrations of CDDP for 48 h after transfection with siRNA for NTC, transfection agent only, and MUC1 (siMUC1#1, and #2) (upper panel, T24CR cells; lower panel, UMUC3CR cells). ** P < .01. *** P < .001
blot analysis also revealed that protein expression of p-AKT and MDR1 were reduced by NVP-BEZ235 in a dose-dependent manner.

### 3.2.4 | MUC1-C stabilizes xCT expression and enhances ROS defenses

We also confirmed whether MUC1-C stabilized xCT, which enhances antioxidant defenses by modulating intracellular oxidative stress. In the western blot analysis, the protein expression of xCT was significantly higher in T24CR cells than in T24WT cells (Figure 4A). As CHX is a protein synthase inhibitor that decomposes xCT, an analysis of the stability of xCT in the presence of CHX further demonstrated that the xCT half-life increased in both CR cells, which suggested that MUC1-C contributed to the stabilization of xCT (Figure S2).

We also measured intracellular GSH levels in T24CR cells treated with CDDP or L-buthionine-sulfoximine (BSO), an inhibitor of GSH synthesis (Figure 4B). Intracellular GSH levels in T24CR cells treated with 1 or 10 μmol/L CDDP were 2.53-fold and 2.00-fold higher than those in T24WT cells (P < .001, P = .001, respectively). Following the addition of 100 μmol/L BSO, GSH synthesis was inhibited in both cell lines (P = .469). As shown in Figure 4C, the amount of intracellular ROS induced by CDDP in T24WT cells was significantly higher than that in T24WT cells treated with vehicle control (4.4-fold increase in cells with 10 μmol/L CDDP than those without in WT cells). However, no difference on the amount of intracellular ROS was observed in T24CR cells between treated with or without CDDP.

When we down-regulated MUC1 with siRNA, the protein expression of xCT was lower than in cells transfected with NTC (Figure 4D). As shown in Figure 4E, intracellular GSH levels in T24CR cells treated with the vehicle control and 1 or 10 μmol/L CDDP after transfection with siMUC1 were significantly lower than those in their counterpart T24CR cells with NTC. As a result, after the transfection with siMUC1, the amount of intracellular ROS in T24CR cells treated with 10 μM CDDP was significantly higher than that in T24CR cells treated with vehicle control (Figure 4F). However, after transfection with NTC no difference on the amount of intracellular ROS was observed in T24CR cells between treated with or without CDDP.

Similar results were obtained upon interactions between UMUC3WT and UMUC3CR cells (Figure S3).

### 3.2.5 | The MUC1-C inhibitor (GO-203) restores sensitivity to CDDP in CR UC cell lines

We attempted to use the MUC1-C inhibitor, GO-203, to confirm whether the combination of CDDP with the MUC1-C inhibitor exerts cytotoxic effects in CR cells. We added 5 μmol/L of CP-2 as the control and GO-203 to T24CR and UMUC3CR cells. RT-PCR analysis shows that the mRNA levels of ABCB1 were significantly inhibited to 18.3 and 10.5% with 5 μmol/L GO-203 in T24CR and UMUC3CR cells (P < .001, P < .001, respectively) (Figure 5A). Western blot analysis also confirmed that p-AKT, MDR1, and xCT protein levels were all decreased (Figure 5B). We compared the cell viabilities of T24CR and UMUC3CR cells treated with 5 μmol/L GO-203 and various concentrations of CDDP for 48 h. We used the vehicle control CP-2 with CDDP (Figure 5C). In T24CR cells, 2.5 μmol/L or higher CDDP with the combination of 5 μmol/L GO-203 exhibited significantly higher cytotoxicity than CP-2 (99.2 ± 4.6% vs 76.5 ± 1.0% with 2.5 μmol/L CDDP, P = .009; Figure 5C, upper panel). Similarly, 10 μmol/L or higher of CDDP with a combination of 5 μmol/L GO-203 exhibited significantly higher cytotoxicity than CP-2 (74.4 ± 5.0% vs 46.3 ± 1.7% with 10 μmol/L CDDP, P < .001; Figure 5C lower panel) in UMUC3CR cells.

### 3.2.6 | In vivo study using UC xenograft model

To verify these results in in vivo experiments, we performed an animal study to evaluate the therapeutic effects of GO-203 in combination with CDDP. On day 25 after the start of treatment, the mean ± SD of tumor volume in mice treated with GO-203 alone was 480.4 ± 93.2 mm³, which was significantly lower than that in mice treated with vehicle control (936.3 ± 134.1 mm³, P = .012). Furthermore, the mean ± SD of tumor volume in mice treated with the combination of CDDP and GO-203 was 89.8 ± 65.5 mm³, which was significantly lower than that in mice treated with GO-203 alone (P = .044) and CDDP alone (847.9 ± 144.0 mm³, P < .001; Figure 5D). Moreover, there were no apparent toxicities, such as a decrease in body weight or hair loss in mice in any treatment group.

### 4 | DISCUSSION

In the present study, immunohistochemistry results indicated that MUC1-C expression was significantly associated with poor survival in UC patients who received CDDP-based perioperative chemotherapy, which suggests the therapeutic resistance of CDDP in surgically treated UC patients. Moreover, we found that MUC1-C plays a critical role in the up-regulated transcription of ABCB1/MDR1 and stabilization of xCT protein expression in UC cells, which contributed to acquired chemoresistance with long-term exposure to CDDP (Figure 5E). This is the first study to examine the functional role of MUC1-C expression in the acquisition of CDDP resistance in UC.

One of the primary mechanisms by which cancer cells attain drug resistance is via the up-regulation of a family of ABC transporters. These transporters or drug efflux pumps contribute to promote the efflux of anticancer drugs. The ABCB1 gene, which encodes for MDR1, is also a well-characterized ABC transporter to reduce drug accumulation inside cancer cells. In the present study, we found that the expression of ABCB1/MDR1 was significantly higher in CR cells than in WT cells, which suggests the close-link of MDR1 and CDDP resistance. Indeed, we confirmed that down-regulation of the ABCB1 gene resulted in the recovery of significant cytotoxic
effects in UC cells (Figure S1). These results suggested that targeting ABCB1 may recover CDDP sensitivity in UC cells even under a CR environment. However, one of the biggest barriers to the use of MDR1 inhibitors is that toxicity is severe, because P-glycoprotein has critical functions in various normal tissues. Therefore, the present study focused on MUC1-C oncoprotein, as this agent is known to promote PI3K-AKT-mTOR signaling by accelerating AKT phosphorylation. Previous studies have demonstrated that the PI3K-AKT-mTOR pathway regulates the gene expression of ABCB1 in various cancers. Nath et al and Jin et al also reported that the hyperactivation of the PI3K/AKT pathway was responsible for regulating the overexpression of the mdr genes, such as ABCC1, ABCC3, ABCC5, and ABCB1. Thus, we expected that the regulation of the PI3K/AKT pathway would contribute to inhibit excessive MDR1 expression, which is responsible for chemoresistance. In the present study, we found that MUC1-C was strongly expressed in CR cells, and acted as a trigger for activation of phosphorylation of the AKT-mTOR-S6K1 pathway. The addition of the AKT-mTOR inhibitor, NVP-BEZ235, clearly resulted in the inhibition of MDR1 protein expression and recovered certain cytotoxic effects of CDDP in CR cells. These results demonstrated that MDR1 expression is regulated by PI3K-AKT-mTOR signaling through MUC1-C expression. Thus, we found
FIGURE 5 The MUC1-C inhibitor GO-203 restores sensitivity to cisplatin (DDP) in chemoresistant tumor cells. A, mRNA expression of ABCB1 in T24CR and UMUC3CR cells treated with 5 µM control peptide (CP-2) and 5 µM GO-203. ***P < .001. B, Protein expression of MUC1-C, total-AKT, p-AKT, MDR1, xCT, and β-actin after a 48-h exposure to CP-2 and after 24-h and 48-h exposures to GO-203. C, The cell viabilities of T24CR cells and UMUC3CR cells exposed to various concentrations of DDP with a combination of 5 µM CP-2 or 5 µM GO-203 48 h after exposure (upper panel, T24CR cells; lower panel, UMUC3CR cells). *P < .05, **P < .01, and ***P < .001. D, Treatment in vivo. UMUC3CR cells (2 × 10^6) were implanted subcutaneously into the flank of nude mice. When a palpable tumor had developed, each group of 8 mice were treated with vehicle control of CP-2 (daily ip injection of 18 mg/kg), DDP alone, or a combination of DDP and GO-203. (Upper panel) Representative subcutaneous tumors from mice treated with CP-2 (vehicle), DDP alone, or a combination of DDP and GO-203. (Lower panel) Growth of tumor volume in each group. Mean tumor volumes are shown in mm^3. * P = .012, vehicle control vs GO-203 alone; * P = .044, GO-203 alone vs the combination of DDP and GO-203; ***P < .001, DDP alone vs the combination of DDP and GO-203. E, Schema of the functional role of MUC1-C for the acquisition of DDP resistance by UC cells. MUC1-C promotes ABCB1/MDR1 expression via PI3K/AKT pathway activation. MDR1 functions as an energy-dependent efflux pump to discharge DDP from tumor cells. MUC1-C also contributes to the stabilization of xCT protein expression. xCT stabilization interacts to increase intracellular GSH levels, which results in a decrease in ROS production. The 2 crucial mechanisms induce DDP resistance upon UC cells that knockdown of MUC1 recovered DDP sensitivity in CR cells by suppressing MDR1 expression.

Another known mechanism for acquiring chemoresistance in UC cells is that cancer cells have cystine/glutamine transporters to increase intracellular GSH levels and enhance cellular defenses against oxidative stress. Furthermore, we recently found that MUC1-C stabilized xCT expression, which subsequently led to the acquisition of oxidative stress, the present results indicated that MUC1-C plays a crucial role in stabilizing xCT expression in an acquired CR environment, and has the potential to be a novel targeting agent for restoring sensitivity to DDP in chemoresistant cells.

Given these findings, we expected that MUC1-C inhibitor, GO-203, can be considered as a promising therapy for overcoming the chemoresistance in UC cells. MUC1-C contains CQC residues in the cytoplasmic domain that are necessary for its homodimerization and function as an oncprotein. GO-203 blocks this CQC motif, and inhibits the function of MUC1-C as an intracellular signaling protein. GO-203 was shown previously to be effective at inhibiting cell proliferation in an in vitro assay and in xenograft models of breast, esophageal, lung, and colorectal carcinomas. The present study demonstrated that the targeting of MUC1-C with GO-203 inhibited p-AKT in UC cells, which suppressed the downstream target, MDR1. Furthermore, GO-203 also destabilized the xCT-MUC1-C link by directly inhibiting MUC1-C homodimerization. The antitumor effect of GO-203 was also confirmed in mice inoculated with CR UC cells in a UC murine xenograft model. Compared with the vehicle control group, UMUC3CR tumor growth was inhibited in GO-203 treated mice. Notably, while UMUC3CR tumors did not respond to DDP alone because of acquired chemoresistance, the combination of GO-203 with DDP revealed significant tumor regression. These findings indicated that GO-203 restores DDP sensitivity in CR UC tumors by inhibiting the function of MUC1-C. Further study is warranted to confirm the detailed toxicity profiles to introduce GO-203 in a clinical setting for UC patients.

In conclusion, we demonstrated the prognostic role of MUC1-C expression in patients with UC treated with DDP-based perioperative chemotherapy. MUC1-C contributed to enhancing MDR1 expression by activating the PI3K-AKT-mTOR pathway, which reduced DDP sensitivity. Furthermore, MUC1-C contributed to stabilizing xCT expression, which subsequently led to the acquisition of oxidative defenses by increasing intracellular GSH levels. The down-regulation of MUC1 contributed to the restoration of DDP sensitivity by inhibiting MDR1 expression and destabilizing xCT. The combination treatment of DDP and GO-203, a MUC1-C inhibitor, may be a promising approach to overcome chemoresistance in UC cells. These functional interactions between MUC1-C, MDR1, and xCT in UC cells will broadly provide useful information for creating new therapeutic strategies to overcome chemoresistance.

ACKNOWLEDGMENTS
This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (#10649875). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

CONFLICTS OF INTEREST
Dr. Donald Kufe holds equity in Genus Oncology and is a consultant to the company. The other authors disclosed no potential conflicts of interest.

ORCID
Keisuke Shigeta https://orcid.org/0000-0002-9405-9446
Eiji Kikuchi https://orcid.org/0000-0002-1624-6676
Takeo Kosaka https://orcid.org/0000-0002-4371-4594
Shuji Mikami https://orcid.org/0000-0002-2978-2187
Mototsugu Oya https://orcid.org/0000-0002-2048-4263
REFERENCES

1. Alfred Witjes J, Lebret T, Comperat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71:462-475.

2. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988;139:461-469.

3. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and vinorelbine in advanced urothelial carcinoma: a randomized, multinational, phase III study. J Clin Oncol. 2000;18:3068-3077.

4. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015-1026.

5. Wu CP, Hsieh YJ, Murakami M, et al. Human ATP-binding cassette efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther. 2015;149:1-123.

6. Wu CP, Hsieh YJ, Murakami M, et al. Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. Biochem Pharmacol. 2018;155:316-325.

7. Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia. 2010;12:628-636.

8. Ueda K. ABC proteins protect the human body and maintain optimal health. Biosci Biotechnol Biochem. 2011;75:401-409.

9. Zutz A, Gompf S, Schagger H, Tampe R. Mitochondrial ABC proteins in health and disease. Biochim Biophys Acta. 2009;1787:681-690.

10. Lewerenz J, Hewett SJ, Huang Y, et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013;18:522-555.

11. Ishimoto T, Nagano Y, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19:387-400.

12. Hasegawa M, Takahashi H, Rajabi H, et al. Functional interactions of the cystine/glutamate antiporter, CD44v7 and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget. 2016;7:11756-11769.

13. Ogihara K, Kikuchi E, Okazaki S, et al. Sulfasalazine can modulate the CD44v7-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer. Cancer Sci. 2019;110:1431-1441.

14. Khodarev NN, Pitroda SP, Beckett MA, et al. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009;69:2833-2837.

15. Kufe D. Oncogenic function of the MUC1 receptor subunit in gene regulation. Oncogene. 2010;29:5663-5666.

16. Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013;32:1073-1081.

17. Ren J, Agata N, Chen D, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 2004;5:163-175.

18. Farahmand L, Merikhan P, Jalili N, Darvishi B, Majidza K. Significant role of MUC1 in development of resistance to currently existing anti-cancer therapeutic agents. Curr Cancer Drug Targets. 2018;18:737-748.

19. Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20:332-342.

20. Soukup V, Capoun O, Cohen D, et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer: a European Association of urology non-muscle invasive bladder cancer guidelines panel systematic review. Eur Urol. 2017;72:801-813.

21. Kikuchi E, Margulis V, Karakiewicz PI, et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol. 2009;27:612-618.

22. Qayyum T, Fyffe G, Duncan M, et al. The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. Br J Cancer. 2012;106:1187-1195.

23. Misra S, Ghatak S, Toole BP. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving alpha-liponurin, phosphoinositide 3-kinase, and ErbB2. J Biol Chem. 2005;280:20310-20315.

24. Huang CZ, Wang YF, Zhang Y, et al. Cepharanthine hydrochloride reverses P-glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway. Oncol Rep. 2017;38:2558-2564.

25. Nath S, Daneshvar K, Roy LD, et al. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis. 2013;2:e51. https://doi.org/10.1038/oncsis.2013.16

26. Jin W, Liao X, Lv Y, et al. MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner. Cell Death Dis. 2017:e2980. https://doi.org/10.1038/cddis.2017.378

27. Sato H, Shiya A, Kimata M, et al. Redox imbalance in cysteine/glutamate transporter-deficient mice. J Biol Chem. 2005;280:37423-37429.

28. Timmerman LA, Holton T, Yuneva M, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24:450-465.

29. Hagiwara M, Kikuchi E, Tanaka N, et al. Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer. BMC Cancer. 2018;18:113. https://doi.org/10.1186/s12885-018-3988-3

30. Raina D, Ahmad R, Joshi MD, et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009;69:5133-5141.

31. Hasegawa M, Sinha RK, Kumar M, et al. Intracellular targeting of the oncogenic MUC1-C protein with a novel GO-203 nanoparticle formulation. Clin Cancer Res. 2015;21:2338-2347.

32. GongSun X, Zhao Y, et al. Inhibition of MUC1-C regulates the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer. Mol Cancer. 2017;16:e1338998. https://doi.org/10.1186/s12943-017-0608-9

33. Ahmad R, Alam M, Hasegawa M, et al. Targeting MUC1-C inhibits the AKT-S6K1-eIF4A pathway regulating TIGAR translation in colorectal cancer. Mol Cancer. 2017;16:33. https://doi.org/10.1186/s12943-017-0608-9

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Shigeta K, Hasegawa M, Kikuchi E, et al. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma. Cancer Sci. 2020;111:3639–3652. https://doi.org/10.1111/cas.14574